垂体后叶素联合普鲁卡因治疗肺结核咯血的疗效观察
|
摘要
目的探讨和分析在肺结核咯血患者中普鲁卡因+垂体后叶素的效果。方法此次抽取2015年3月至2018年3月在本院医治的患者(90例)进行研究,以入院顺序分乙组和甲组,各45例。本次患者均静脉滴注垂体后叶素,而甲组加普鲁卡因,总结止血时间、不良反应、疗效。结果甲组的止血时间(2.15±0.45)天短于乙组(4.82±1.33)天,差异具有统计学意义(t=12.756,P=0.000)。甲组不良反应的总发生率(15.56%)少于乙组(40.0%),差异有统计学意义(c2=6.702,P=0.010)。甲组治疗的总有效率(95.56%)高于乙组(71.11%),差异有统计学意义(c2=6.680,P=0.002)。结论肺结核咯血患者中,普鲁卡因+垂体后叶素可快速止血,治疗有效率高,且具有一定的安全性。
Objective To investigate and analyze the effect of procaine + hypophysis in pulmonary tuberculosis and hemoptysis. Methods The patients(90 cases) who were treated in this hospital from March 2015 to March 2018 were selected for the study. They were divided into group B and group A in the order of admission to the hospital, each with 45 cases. This time, the patients were intravenous drip of pituitary hypophysis, while Group A Jiapuluqiayin summarized the time of bleeding, adverse reactions, and efficacy. Results The hemostasis time of Group A(2.15±0.45) was shorter than that of Group B(4.82±1.33), and the difference was statistically significant(t=12.756, P=0.000). The total incidence of adverse reactions in Group A(15.56%) was less than that in Group B(40.0%), and the difference was statistically significant(c2=6.702, P=0.010). The total effective rate of Group A treatment(95.56%) was higher than Group B(71.11%), and the difference was statistically significant(c2=6.680, P=0.002).Conclusion In tuberculosis hemoptysis, procaine + hypophysis can stop bleeding quickly, the treatment efficiency is high, and it has certain safety.
Objective To investigate and analyze the effect of procaine + hypophysis in pulmonary tuberculosis and hemoptysis. Methods The patients(90 cases) who were treated in this hospital from March 2015 to March 2018 were selected for the study. They were divided into group B and group A in the order of admission to the hospital, each with 45 cases. This time, the patients were intravenous drip of pituitary hypophysis, while Group A Jiapuluqiayin summarized the time of bleeding, adverse reactions, and efficacy. Results The hemostasis time of Group A(2.15±0.45) was shorter than that of Group B(4.82±1.33), and the difference was statistically significant(t=12.756, P=0.000). The total incidence of adverse reactions in Group A(15.56%) was less than that in Group B(40.0%), and the difference was statistically significant(c2=6.702, P=0.010). The total effective rate of Group A treatment(95.56%) was higher than Group B(71.11%), and the difference was statistically significant(c2=6.680, P=0.002).Conclusion In tuberculosis hemoptysis, procaine + hypophysis can stop bleeding quickly, the treatment efficiency is high, and it has certain safety.
引文
[1]王欣,郭珍.肺结核咯血患者支气管动脉栓塞治疗临床效果研究[J].当代医学,2017,23(1):4-6.
[2]Asrar.Elegail,Nuha Ibrahim Mohamed,Eman Mohamed No.Molecular characterization of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Khartoum,Sudan[J].International Journal of Mycobacteriology,2018,7(3):236-241.
[3]Chia-Hung Chen,Wei-Ming Huang,Shih-Hsuan Liang,et al.Does biopsy needle traversing through central portion of lesion increase the risk of hemoptysis during percutaneous transthoracic needle biopsy?[J].Japanese journal of radiology,2018,36(3):231-237.
[4]杨桂丛.普鲁卡因与垂体后叶素联合治疗肺结核咯血[J].医药与保健,2015,20(1):56-57.
[5]辛朝雄,李晓云,谢华丽,等.垂体后叶素联合普鲁卡因治疗肺结核咯血的疗效观察[J].临床医学,2014,33(7):11-12.
[6]周以明.酚妥拉明联合垂体后叶素治疗老年支气管扩张伴大咯血的临床分析[J].当代医学,2016,22(36):173-174.
[7]官玉良.垂体后叶素联合普鲁卡因治疗肺结核咯血的疗效与安全性分析[J].中国继续医学教育,2017,41(27):97-99.
[8]曾家副,陈玉强,黄慧.普鲁卡因针联合脑垂体后叶素治疗咯血疗效观察[J].淮海医药,2016,19(3):325-326.
[9]黄松.普鲁卡因联合肾上腺色腙治疗肺结核大咯血的临床疗效及不良反应[J].医学理论与实践,2017,22(13):1925-1926.
[10]王雪玲,李文革.普鲁卡因联合肾上腺色腙治疗肺结核大咯血临床疗效和不良反应观察[J].现代中西医结合杂志,2014,17(27):2998-2999.
[2]Asrar.Elegail,Nuha Ibrahim Mohamed,Eman Mohamed No.Molecular characterization of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Khartoum,Sudan[J].International Journal of Mycobacteriology,2018,7(3):236-241.
[3]Chia-Hung Chen,Wei-Ming Huang,Shih-Hsuan Liang,et al.Does biopsy needle traversing through central portion of lesion increase the risk of hemoptysis during percutaneous transthoracic needle biopsy?[J].Japanese journal of radiology,2018,36(3):231-237.
[4]杨桂丛.普鲁卡因与垂体后叶素联合治疗肺结核咯血[J].医药与保健,2015,20(1):56-57.
[5]辛朝雄,李晓云,谢华丽,等.垂体后叶素联合普鲁卡因治疗肺结核咯血的疗效观察[J].临床医学,2014,33(7):11-12.
[6]周以明.酚妥拉明联合垂体后叶素治疗老年支气管扩张伴大咯血的临床分析[J].当代医学,2016,22(36):173-174.
[7]官玉良.垂体后叶素联合普鲁卡因治疗肺结核咯血的疗效与安全性分析[J].中国继续医学教育,2017,41(27):97-99.
[8]曾家副,陈玉强,黄慧.普鲁卡因针联合脑垂体后叶素治疗咯血疗效观察[J].淮海医药,2016,19(3):325-326.
[9]黄松.普鲁卡因联合肾上腺色腙治疗肺结核大咯血的临床疗效及不良反应[J].医学理论与实践,2017,22(13):1925-1926.
[10]王雪玲,李文革.普鲁卡因联合肾上腺色腙治疗肺结核大咯血临床疗效和不良反应观察[J].现代中西医结合杂志,2014,17(27):2998-2999.